Archives

In 1950, when the Muscular Dystrophy Association was founded, muscular dystrophy and neuromuscular disease weren’t well known or well understood. But they were, as today, affecting an entire community of…

Researchers at Scholar Rock are looking for individuals with spinal muscular atrophy (SMA) type 3 to participate in a phase 2 study. The goal of the study is to evaluate…

It might only be a month into 2020, but MDA’s advocacy team and grassroots advocates are already making their voices heard. We expect the next 12 months to be crucial…

Australian company Antisense Therapeutics announced encouraging results from its phase 2, open-label clinical trial of the company’s investigational therapy ATL1102 for treating Duchenne muscular dystrophy (DMD). The study met its…

This public health program makes early treatment possible for babies born with neuromuscular diseases

An MDA Ambassador learns to live life to the fullest

Among the advantages of genetic testing, it can confirm a diagnosis and help predict how a disease will progress, giving vital information for treatment.

Meet the winners of Quest’s Lasting Impression Photo Contest

Mikey (left) is in a clinical trial for a DMD therapy. The medication could benefit his brother, Reid (right), and many other boys with DMD. MDA families can get involved…

AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich’s ataxia (FA), was awarded MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio’s phase 2 clinical trial of a…